VivoSim raises $4M in private placement from single healthcare investor
What's the deal? VivoSim Labs (Nasdaq: VIVS) has priced a $4 million private placement with a single, undisclosed healthcare-focused institutional investor. The San Diego company — formerly Organovo Holdings — sells 3D human cellular models used in preclinical drug safety testing.
The terms: The investor is buying 4,705,883 shares of common stock (or equivalents) plus warrants for the same number of shares, at a combined price of $0.85 per share. That yields roughly $4 million in gross proceeds before placement agent fees and other expenses.
On the warrants: The warrants carry an exercise price of $0.85 per share. They become exercisable only after shareholder approval and expire five years from the initial exercise date.
What's the endgame? VivoSim builds what it calls next-generation New Approach Methodologies (NAM) — lab models designed to test drug safety without traditional animal or older cell-based methods.
The signal: The placement was priced at-the-market under Nasdaq rules, a structure smaller listed companies often use to raise capital quickly from a single institutional backer. For a microcap trading at $0.85 a share, the deal keeps cash flowing into a company betting on alternatives to conventional preclinical testing.
Read more: Aktiencheck
Image credit: Jacobs School of Engineering
